Canada markets close in 49 minutes

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
3.5500+0.2700 (+8.23%)
As of 03:11PM EDT. Market open.
Full screen
Previous Close3.2800
Open3.3000
Bid3.5600 x 0
Ask3.6000 x 0
Day's Range2.7000 - 3.6600
52 Week Range2.5000 - 4.7200
Volume77,953
Avg. Volume16,182
Market Cap337.682M
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-0.4760
Earnings DateOct 13, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.49
  • GlobeNewswire

    Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update

    MONTREAL, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13, 2022. The conference call will be held at 8:30 a.m. (ET) on October 13, 2022 to discuss the results and recent business updates. The call will be hoste

  • GlobeNewswire

    Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference

    MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, Sep

  • GlobeNewswire

    Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth

    Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer stem-like cells in vitro and in vivoPaper highlights potential mechanisms by which TH1902 can bypass underlying causes of resistance to docetaxel that can contribute to treatment failure and disease recurrence MONTREAL, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or t